Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 1022-1027

  Xu, Xiao Jun ^a   Tang, Yong Min ^a   Shen, Hong Qiang ^a   Song, Hua ^a   Yang, Shi Long ^a   Shi, Shu Wen ^a   Xu, Wei Qun ^a  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Childhood acute lymphoblastic leukemia; Flow cytometry; Immunophenotype; Minimal residual disease; Regeneration; Relapse

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER RELAPSE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; TREATMENT DURATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862584670     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.014     Document Type: Article

References (21)

1. Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grumayer R., Moricke A., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
2. Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111:5477-5485.
3. Sutton R., Venn N.C., Tolisano J., Bahar A.Y., Giles J.E., Ashton L.J., et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Brit J Haematol 2009, 146:292-299.
4. Basso G., Veltroni M., Valsecchi M.G., Dworzak M.N., Ratei R., Silvestri D., et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009, 27:5168-5174.
5. Cui L., Li Z., Wu M., Li W., Gao C., Deng G. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia. Leuk Res 2010, 34:1314-1319.
6. Bai Y., Yu H., Lin W., Zhou D.F., Xiao Y., Wu X.Y., et al. Detection of minimal residual disease in pediatric patients with acute lymphoblastic leukemia and its prognostic significance. World J Pediatr 2007, 3:290-294.
7. Wang L., Jiang H., Li H., Shao J.B., Lu Z.H., Yang J.W., et al. Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 2011, 32:400-403. (in Chinese).
8. Tie L.J., Gu L.J., Song D.L., Jiang L.M., Xue H.L., Tang J.Y., et al. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China. Zhongguo Dang Dai Er Ke Za Zhi 2009, 11:5-9. (in Chinese).
9. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:1083-1098. vii.
10. Bruggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottmann O.G., et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
11. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?. Leukemia 2007, 21:622-626.
12. Kern W., Voskova D., Schnittger S., Schoch C., Haferlach T. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007, 48:80-88.
13. Tang Y., Xu X., Song H., Yang S., Shi S., Wei J. Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer 2008, 51:380-386.
14. Dworzak M.N., Froschl G., Printz D., Mann G., Potschger U., Muhlegger N., et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002, 99:1952-1958.
15. Mejstrikova E., Fronkova E., Batinic D., Dubravcic K., Kiss F., Kappelmayer J., et al. Standardized 4 color flow cytometric minimal residual disease detection failed to overcome regeneration problems but identifies early blast clearence predictive of molecular remission after induction in childhood B lineage leukemia. Blood 2006, 108:521a-522a.
16. McKenna R.W., Washington L.T., Aquino D.B., Picker L.J., Kroft S.H. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001, 98:2498-2507.
17. Wang Y.R., Jin R.M., Xu J.W., Zhang Z.Q. A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997-2007. Leuk Res 2011, 35:1628-1631.
18. Nachman J.B., Sather H.N., Sensel M.G., Trigg M.E., Cherlow J.M., Lukens J.N., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. New Engl J Med 1998, 338:1663-1671.
19. Ratei R., Basso G., Dworzak M., Gaipa G., Veltroni M., Rhein P., et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009, 23:528-534.
20. Volejnikova J., Mejstrikova E., Valova T., Reznickova L., Hodonska L., Mihal V., et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica 2011, 96:1815-1821.
21. Jaworska-Posadzy A., Styczynski J., Kubicka M., Debski R., Rafinska-Kurylo B., Kolodziej B., et al. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry. Anticancer Res 2011, 31:1453-1457.